<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55326">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01888432</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001H2307</org_study_id>
    <secondary_id>2010-024527-25</secondary_id>
    <nct_id>NCT01888432</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants</brief_title>
  <official_title>A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate the efficacy and safety of everolimus in
      combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver
      transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite efficacy failure of treated biopsy proven acute rejection, graft loss or death in everolimus with reduced tacrolimus group compared to standard tacrolimus</measure>
    <time_frame>at 12 months post transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of composite efficacy failure of treated biopsy proven acute rejection (tBPAR ≥ RAI score 3), graft loss (GL) or death (D) in everolimus with reduced tacrolimus group compared to standard tacrolimus at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function by estimated Glomerular Filtration Rate</measure>
    <time_frame>Randomization, Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Renal function (change in estimated glomerular filtration rate (eGFR)) from randomization to Month 12 post transplantation with everolimus (EVR) in combination with reduced tacrolimus (rTAC) compared to standard exposure tacrolimus (TAC) in living donor liver transplant recipients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare incidence of a composite of tBPAR, graft loss, death. Incidenceof each component of the composite. Incidenceof a composite of death or graft loss. Incidence of BPAR, tAR and AR.</measure>
    <time_frame>Month 12 and Month 24 post transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare between the treatment group EVR with rTAC vs standard TAC: incidence of a composite of tBPAR, graft loss, death. Incidenceof each component of the composite. Incidenceof a composite of death or graft loss. Incidence of BPAR, tAR and AR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare tBPAR and tAR by severity (RAI grading) as well as diagnosis leading to transplantation</measure>
    <time_frame>Month 6, Month 12 and Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare tBPAR and tAR by severity (RAI grading) as well as diagnosis leading to transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treated BPAR by time to event, severity, and diagnosis leading to transplantation</measure>
    <time_frame>Month 12 and Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of treated BPAR by time to event, severity, and diagnosis leading to transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare evolution of post-randomization renal function over time assessed by the change by eGFR</measure>
    <time_frame>Randomization, Month 12 and Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare evolution of post-randomization renal function over time assessed by the change in estimated GFR (MDRD-4), including changes from randomization to Months 12 and 24. Rate of change of renal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function and change in eGFR in subgroups</measure>
    <time_frame>Randomization, Month 6 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Renal function and change in estimated GFR in subgroups including age (&lt; 60 and ≥ 60 years), gender, race, region, renal function strata, HCV status, MELD score categories, and diagnosis leading to transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio at various time points</measure>
    <time_frame>Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urinary protein/creatinine ratio at various time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare rate of recurrence and time to recurrence of HCC in subjects with a diagnosis of HCC at the time of liver transplantation</measure>
    <time_frame>Randomization, Month12 and Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare rate of recurrence and time to recurrence of HCC in subjects with a diagnosis of HCC at the time of liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare tumor-free survival in subjects with a diagnosis of HCC at the time of liver transplantation</measure>
    <time_frame>Randomization, Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare tumor-free survival in subjects with a diagnosis of HCC at the time of liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare HCV viral load (overall and by genotype).</measure>
    <time_frame>Month 12 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare HCV viral load (overall and by genotype).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare rate of progression of HCV related allograft fibrosis.</measure>
    <time_frame>Randomization, Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare rate of progression of HCV related allograft fibrosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare incidence  of  AEs  and  SAEs  including  infections  and  serious infections, overall, by body system and preferred term</measure>
    <time_frame>Month 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare incidence  of  AEs  and  SAEs  including  infections  and  serious infections, overall, by body system and preferred term</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus + reduced tacrolimus ± corticosteroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard tacrolimus ± corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus + reduced tacrolimus</intervention_name>
    <description>Everolimus will be initiated at Week 4 post transplantation. The dose will be adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus will be reduced to 3-5 ng/mL.</description>
    <arm_group_label>Everolimus + reduced tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard tacrolimus</intervention_name>
    <description>Tacrolimus will be initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should be 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.</description>
    <arm_group_label>Standard tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Written informed consent

          -  Subject aged ≥18 years of a primary, orthotopic liver allograft, from a living donor

          -  Subject negative for HIV

        Incusion criteria at Randomization:

        - Subject was initated on tacrolimus-based immunosuppressive regimen with steroids and
        other immunosuppression

        Exclusion criteria:

          -  Subjects transplanted for acute liver failure

          -  HCV negativesubjects receiving a transplant from HCV positive donor

          -  Subjects receiving multiple solid organ (including multiple liver lobes/segments) or
             islet cell tissue transplants, or have previously received an organ or tissue
             transplant.

          -  Subjects receiving an ABO incompatible allograft.

          -  MELD-score &gt; 35 within 1 month prior to transplantation.

          -  Use of immunosuppressive or antibody induction agents not specified in the protocol.

          -  History of malignancy of any organ system (except hepatocellular carcinoma or
             localized basal cell carcinoma of the skin)

          -  Hepatocellular carcinoma with extrahepatic spread or macrovascular invasion

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test.

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             during dosing and for 2 weeks of the last dose of study medication

          -  History of hypersensitivity to any of the study drugs or to drugs with similar
             chemical class, or to any of the excipients

        Exclusion criteria at Randomization:

          -  Any post-transplant history of thrombosis, occlusion or stent placement in any major
             hepatic artery, major/reconstructed hepatic vein, portal vein or inferior vena cava
             at any time during the run-in period prior to randomization.

          -  Subjects with a confirmed spot urine protein/creatinine ratio that indicates ≥ 1.0
             g/24 hrs of proteinuria

          -  Subjects who have severe hypercholesterolemia (&gt;350 mg/dL; &gt;9 mmol/L) or
             hypertriglyceridemia (&gt;500 mg/dL; &gt;8.5 mmol/L) at randomization.

          -  Subjects with platelet count &lt; 30,000/mm3.

          -  Subjects with an absolute neutrophil count of &lt; 1,000/mm³ or white blood cell count
             of &lt; 2,000/mm³.

          -  Subjects with systemic infection requiring active use of IV antibiotics.

          -  Subjects requiring life support measures such as ventilation, dialysis, vasopressor
             agents.

          -  Subjects who require renal replacement therapy within 7 days prior to randomization.

          -  Subjects with detectable HBV DNA at time of randomization

          -  Subjects meeting the following criteria for acute rejection during the run in period:

               -  Any acute rejection in the week prior to randomization.

               -  2 treated acute rejections.

               -  Any rejection requiring antibody treatment.

               -  Any severe cellular (and/or any humoral) rejection. Other protocol-defined
                  inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122 001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682 026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600006</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>738-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119260</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Ko</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mecidiyekoy/Istanbul</city>
        <zip>34394</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>June 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver transplantation</keyword>
  <keyword>everolimus</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>reduced calcineuron inhibitor</keyword>
  <keyword>renal function</keyword>
  <keyword>living donor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
